RECRUITING

Cannabis Use and Outcomes in Black and White Patients With Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of the observational study is to learn how black and white patients with solid tumor cancer use cannabis, opioids and tobacco. The investigators are using momentary ecological assessment through a smart phone app and surveys to assess patient-reported pain and other symptoms as to inform clinical practice and guidelines for underrepresented populations.

Official Title

Cannabis Use and Outcomes in Black and White Patients With Cancer

Quick Facts

Study Start:2023-03-30
Study Completion:2027-03-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06037681

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 21 years or older
  2. * Black or white race
  3. * Solid tumor cancer within 3 years of enrollment
  4. * Cannabis use of at least once a week or non cannabis use for 3 months
  5. * experience pain but spend less than 50% in bed or chair
  6. * Prescribed or take opioid for at least 30 days for pain
  7. * Not pregnant or planning to become pregnant in the next 12 months
  8. * English speaking
  1. * Lymphoma, leukemia, and melanoma
  2. * CBD only use
  3. * Synthetic cannabis use in past 3 months = Prescribed Medically-prescribed synthetic cannabis (e.g., dronabinol \[Marinol, Syndros\], Epidiolex)
  4. * race other than Black or White

Contacts and Locations

Study Contact

Colleen Kilanowski, MS
CONTACT
716-829-5977
ckk@buffalo.edu
Rebecca L Ashare, BA
CONTACT
716-829-2024
rlashare@buffalo.edu

Principal Investigator

Salimah Meghani, PhD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Brooke Worster, MD
PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Rebecca L Ashare, PhD
PRINCIPAL_INVESTIGATOR
University at Buffalo

Study Locations (Sites)

University at Buffalo
Buffalo, New York, 14214
United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19144
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19176
United States

Collaborators and Investigators

Sponsor: State University of New York at Buffalo

  • Salimah Meghani, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania
  • Brooke Worster, MD, PRINCIPAL_INVESTIGATOR, Thomas Jefferson University
  • Rebecca L Ashare, PhD, PRINCIPAL_INVESTIGATOR, University at Buffalo

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-30
Study Completion Date2027-03-30

Study Record Updates

Study Start Date2023-03-30
Study Completion Date2027-03-30

Terms related to this study

Keywords Provided by Researchers

  • Solid tumor, opioids, cannabis

Additional Relevant MeSH Terms

  • Cancer